Literature DB >> 1358908

Antibodies to Puumala virus in humans determined by neutralization test.

J Hörling1, A Lundkvist, J W Huggins, B Niklasson.   

Abstract

An assay for detection of neutralizing antibodies to Puumala virus using 96-well microtiter plates (NT-ELISA) was developed and evaluated. The test proved to have similar sensitivity and specificity as an IgG ELISA and indirect immunofluorescence test, when screening 187 sera (with an antibody prevalence rate of 19%) from normal populations in an endemic area of Nephropathia epidemica (NE) in Sweden. NE-patients monitored for 2 years had neutralizing antibodies in early sera collected 1-4 days after the onset of disease with a continuous increase in neutralizing antibodies with time. Furthermore, high titers of neutralizing antibodies were detected 10-20 years post-infection. This neutralization assay was also evaluated as a screening method in the production of monoclonal antibodies. The format of the NT-ELISA makes it feasible to screen a large number of specimens with results similar to the standard plaque or focus-reduction neutralization tests.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358908     DOI: 10.1016/0166-0934(92)90132-w

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  15 in total

1.  Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques.

Authors:  J Klingström; A Plyusnin; A Vaheri; A Lundkvist
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Antigenic properties and diagnostic potential of puumala virus nucleocapsid protein expressed in insect cells.

Authors:  O Vapalahti; A Lundkvist; H Kallio-Kokko; K Paukku; I Julkunen; H Lankinen; A Vaheri
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

Review 3.  Human pathogenic hantaviruses and prevention of infection.

Authors:  Detlev H Krüger; Günther Schönrich; Boris Klempa
Journal:  Hum Vaccin       Date:  2011-06-01

4.  Evaluation of serological methods for diagnosis of Puumala hantavirus infection (nephropathia epidemica).

Authors:  K B Sjölander; F Elgh; H Kallio-Kokko; O Vapalahti; M Hägglund; V Palmcrantz; P Juto; A Vaheri; B Niklasson; A Lundkvist
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

5.  Immunoglobulin G subclass responses against the structural components of Puumala virus.

Authors:  A Lundkvist; S Björsten; B Niklasson
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

6.  The humoral response to Puumala virus infection (nephropathia epidemica) investigated by viral protein specific immunoassays.

Authors:  A Lundkvist; J Hörling; B Niklasson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

7.  Detection and subsequent sequencing of Puumala virus from human specimens by PCR.

Authors:  J Hörling; A Lundkvist; K Persson; M Mullaart; T Dzagurova; A Dekonenko; E Tkachenko; B Niklasson
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

8.  Puumala hantavirus viremia diagnosed by real-time reverse transcriptase PCR using samples from patients with hemorrhagic fever and renal syndrome.

Authors:  Magnus Evander; Irene Eriksson; Lisa Pettersson; Per Juto; Clas Ahlm; Gert E Olsson; Göran Bucht; Annika Allard
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

9.  Anti-idiotypic antibodies against Puumala virus glycoprotein-specific monoclonal antibodies inhibit virus infection in cell cultures.

Authors:  A Lundkvist; C Scholander; B Niklasson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 10.  Immune response during hantavirus diseases: implications for immunotherapies and vaccine design.

Authors:  Farides Saavedra; Fabián E Díaz; Angello Retamal-Díaz; Camila Covián; Pablo A González; Alexis M Kalergis
Journal:  Immunology       Date:  2021-03-18       Impact factor: 7.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.